What is BioRestorative Therapies, Inc.'s earnings per share (EPS)?

BioRestorative Therapies, Inc. (BRTX) reported diluted earnings per share of -$1.58 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BioRestorative Therapies, Inc. (BRTX) Financials

BRTX

FY2025 annual

Revenue $360K -10.3% YoY

Net Income -$14.2M -58.6% YoY

EPS (Diluted) -$1.58 YoY not available

Free Cash Flow -$10.9M -30.8% YoY

Market Cap $2.1M as of Oct 17, 2026

Price / Sales 5.9x on $358K revenue, trailing 12 months to March 31, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to March 31, 2026

Price / Book 0.7x on $3.0M equity, Q1 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BRTX SEC filings page.

BioRestorative Therapies, Inc. (BRTX) reported $360K in revenue for fiscal year 2025, down 10.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BRTX FY2025 2026-10-04

The business remains a development-led model with tiny sales, heavy research spending, and a thinner balance sheet.

A high gross margin is not yet evidence of a commercial engine: FY2025 R&D reached $10.1M against revenue of $360K, so reported activity is dominated by development rather than sales. Cash conversion is also weak: free cash flow was -$10.9M, nearly matching operating cash flow of -$10.8M, which means capital spending was not the main source of cash use.

FY2025’s liquidity posture deteriorated sharply: current ratio was 0.8x while debt-to-equity reached 10.4x. That placed near-term obligations above current assets and left a thin equity cushion; the reported liquidity comparison was 3.3 months of latest annual operating outflow.

Revenue remained only $360K in FY2025 while R&D spending reached $10.1M, so the cost structure is built around development rather than commercial scale. The share base rose from 7.5M to 25.5M, indicating a materially changed funding structure alongside continued cash use.

Financial Health Signals

Financial health score not available

BioRestorative Therapies, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-70.71

BioRestorative Therapies, Inc. scores -70.71, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.1M) relative to total liabilities ($3.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

BioRestorative Therapies, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

BioRestorative Therapies, Inc. reported a net loss of $14.2M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

BioRestorative Therapies, Inc. reported an operating loss of $15.6M against $266K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$23K

YoY-7.3%

QoQ+18.2%

5Y CAGR+5.2%

10Y CAGR+9.8%

BioRestorative Therapies, Inc. generated $23K in revenue in Q1 2026. This represents a decrease of 7.3% from the same quarter a year earlier. Against the prior quarter it is up 18.2%.

EBITDA

-$3.3M

YoY+29.9%

QoQ+11.6%

BioRestorative Therapies, Inc.'s EBITDA was -$3.3M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 29.9% from the same quarter a year earlier. Against the prior quarter it is up 11.6%.

Net Income

-$2.2M

YoY+59.7%

QoQ+32.8%

BioRestorative Therapies, Inc. reported -$2.2M in net income in Q1 2026. This represents an increase of 59.7% from the same quarter a year earlier. Against the prior quarter it is up 32.8%.

EPS (Diluted)

-$0.12

BioRestorative Therapies, Inc. earned -$0.12 per diluted share (EPS) in Q1 2026.

Cash & Balance Sheet

Cash & Debt

$3.1M

YoY+153.3%

QoQ+106.0%

5Y CAGR+4.5%

10Y CAGR+24.3%

BioRestorative Therapies, Inc. held $3.1M in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

25M

5Y CAGR-61.9%

10Y CAGR+20.4%

BioRestorative Therapies, Inc. had 25M shares outstanding in Q1 2026.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Gross Margin

68.1%

YoY-20.2pp

QoQ-23.5pp

BioRestorative Therapies, Inc.'s gross margin was 68.1% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is down 20.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 23.5 percentage points.

Return on Equity

-71.2%

YoY+15.7pp

QoQ+827.9pp

BioRestorative Therapies, Inc.'s ROE was -71.2% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 15.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 827.9 percentage points.

Operating Margin

Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$1.9M

YoY-27.2%

QoQ-26.7%

5Y CAGR+63.4%

10Y CAGR+8.3%

BioRestorative Therapies, Inc. invested $1.9M in research and development in Q1 2026. This represents a decrease of 27.2% from the same quarter a year earlier. Against the prior quarter it is down 26.7%.

Share Buybacks

BioRestorative Therapies, Inc. repurchased no shares in Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

BRTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BRTX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$358K	$360K-10.3%	$401K+175.0%	$146K+21.7%	$120K+160.4%	$46K-40.3%	$77K-40.8%	$130K+17.1%	$111K+37.0%	$81K+122.8%	$36K-94.2%	$629K+51.2%	$416K+24661.7%	$2K-89.2%	$16K	$0
Cost of Revenue	$28K	$24K-15.1%	$28K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$102-100.0%	$262K+22.3%	$214K+102704.8%	$208-84.1%	$1K	$0
Gross Profit	$330K	$336K-9.9%	$373K+155.8%	$146K	N/A	N/A	N/A	N/A	N/A	$81K+123.4%	$36K-90.1%	$367K+81.7%	$202K+13633.8%	$1K-89.7%	$14K	$0
R&D Expenses	$9.4M	$10.1M+50.5%	$6.7M+66.2%	$4.0M+14.8%	$3.5M+381.9%	$729K-16.9%	$877K-49.1%	$1.7M+13.8%	$1.5M-29.7%	$2.2M-25.4%	$2.9M+37.0%	$2.1M+47.1%	$1.4M-10.3%	$1.6M+110.6%	$757K+6206.5%	$12K
SG&A Expenses	$5.2M	$5.9M+12.8%	$5.2M-53.9%	$11.3M-27.3%	$15.6M-39.2%	$25.6M+1334.2%	$1.8M-61.2%	$4.6M+14.5%	$4.0M+3.1%	$3.9M+20.3%	$3.2M-16.1%	$3.9M+71.4%	$2.3M-0.3%	$2.3M-23.3%	$3.0M	N/A
Operating Income	-$14.2M	-$15.6M-35.4%	-$11.6M+24.1%	-$15.2M+19.8%	-$19.0M+27.9%	-$26.3M-855.9%	-$2.8M	N/A	N/A	-$8.4M-7.6%	-$7.8M-8.6%	-$7.2M-45.7%	-$4.9M-3.6%	-$4.8M+14.7%	-$5.6M	N/A
EBITDA	N/A	-$15.4M-35.8%	-$11.4M+24.5%	-$15.1M+20.1%	-$18.9M+28.1%	-$26.2M-896.6%	-$2.6M	N/A	N/A	-$8.1M-7.8%	-$7.5M-8.2%	-$7.0M-44.2%	-$4.8M-3.8%	-$4.6M+15.2%	-$5.5M	N/A
Interest Expense	N/A	$266K-56.8%	$616K+11.5%	$552K+4640.7%	$12K+100.6%	-$1.8M	N/A	N/A	N/A	$208K+2048.9%	$10K-96.3%	$264K-7.6%	$285K-23.2%	$371K-37.3%	$592K+127.6%	$260K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	N/A	N/A
Net Income	-$11.1M	-$14.2M-58.6%	-$9.0M+13.8%	-$10.4M+21.2%	-$13.2M+70.2%	-$44.3M-293.0%	-$11.3M	N/A	N/A	N/A	N/A	-$7.9M-41.8%	-$5.6M+2.8%	-$5.8M	N/A	N/A
EPS (Basic)	N/A	-$1.58-36.2%	-$1.16+53.0%	-$2.47+32.3%	-$3.65+90.2%	-$37.30	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$1.58	-$1.16	-$2.47+32.3%	-$3.65	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	9M	8M	4M+16.6%	4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Revenue	$23K-7.3%	$20K-54.7%	$12K-94.9%	$303K+240.4%	$25K-28.6%	$43K+124.4%	$234K+660.9%	$89K+38.1%
Cost of Revenue	$7K+153.9%	$2K	$11K-42.1%	$9K+34.5%	$3K	N/A	$18K	$6K
Gross Profit	$16K-28.5%	$18K-55.0%	$1K-99.4%	$295K+256.6%	$22K-36.9%	$40K	$215K+601.5%	$83K+28.1%
R&D Expenses	$1.9M-27.2%	$2.6M-4.2%	$2.6M+78.5%	$2.2M+53.1%	$2.6M+150.1%	$2.7M+151.5%	$1.5M+79.5%	$1.5M+61.0%
SG&A Expenses	$1.5M-32.4%	$1.2M+10847.0%	$1.1M+6.3%	$1.4M+25.2%	$2.2M-29.3%	-$11K-100.5%	$1.0M-54.9%	$1.1M-51.8%
Operating Income	-$3.4M+29.6%	-$3.8M-42.2%	-$3.7M-62.2%	-$3.3M-33.9%	-$4.8M-17.0%	-$2.7M+16.5%	-$2.3M+26.3%	-$2.5M+20.8%
EBITDA	-$3.3M+29.9%	-$3.8M-42.9%	-$3.7M-63.3%	-$3.3M-34.3%	-$4.8M-16.9%	-$2.6M	-$2.2M+26.9%	-$2.4M
Interest Expense	N/A	$35K-70.9%	$58K-63.6%	$74K-58.0%	$100K-38.5%	$119K-68.4%	$159K+157.1%	$176K+82.9%
Net Income	-$2.2M+59.7%	-$3.2M-96.0%	-$3.0M-178.4%	-$2.7M+34.1%	-$5.3M-140.2%	-$1.6M+29.0%	-$1.1M-122.9%	-$4.0M+29.4%
EPS (Basic)	-$0.12+81.3%	-$0.32-60.0%	-$0.33-153.8%	-$0.30+40.0%	-$0.64-93.9%	-$0.20+57.4%	-$0.13-112.5%	-$0.50+66.0%
EPS (Diluted)	-$0.12	-$0.32	-$0.33-153.8%	-$0.30+40.0%	-$0.64-93.9%	-$0.20	-$0.13-133.3%	-$0.50
Diluted Shares (Avg)	18M	N/A	9M+12.2%	9M+7.6%	8M+25.3%	N/A	8M-34.1%	8M

Not reported in any period shown, so not listed: Income Tax.

BRTX Balance Sheet

BRTX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$4.1M-66.8%	$12.3M-2.6%	$12.6M-23.3%	$16.4M-26.8%	$22.5M+416.5%	$4.3M+196.5%	$1.5M+23.0%	$1.2M-32.2%	$1.8M+11.3%	$1.6M-21.7%	$2.0M+19.2%	$1.7M+22.3%	$1.4M+9.1%	$1.3M+473.8%	$221K
Current Assets	$3.1M-71.9%	$11.1M-2.2%	$11.4M-24.7%	$15.1M-29.5%	$21.5M+573.6%	$3.2M+4528.1%	$69K-62.0%	$181K-65.2%	$520K+608.1%	$73K-74.6%	$289K+153.1%	$114K-52.3%	$240K+666.6%	$31K-73.6%	$118K
Cash & Equivalents	$1.5M+175.8%	$548K-38.0%	$884K-48.4%	$1.7M-91.8%	$21.0M+586.1%	$3.1M+184071.3%	$2K-98.6%	$118K-74.0%	$452K+1319.4%	$32K-80.9%	$167K+81.4%	$92K-54.4%	$201K+55298.9%	$363-99.5%	$72K
Short-Term Investments	$1.4M-85.8%	$10.2M0.0%	$10.2M-21.9%	$13.0M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2K-89.2%	$18K+43.9%	$12K	$0
Accounts Receivable	$16K-91.8%	$188K+876.2%	$19K+20.6%	$16K+220.0%	$5K-70.6%	$17K-46.9%	$32K+10.3%	$29K-23.7%	$38K+533.3%	$6K-93.6%	$93K	$0	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$3.7M-0.7%	$3.7M+43.8%	$2.6M-57.6%	$6.1M-47.4%	$11.7M+105.5%	$5.7M-60.1%	$14.2M+44.8%	$9.8M+14.4%	$8.6M+30.6%	$6.6M+11.1%	$5.9M-30.9%	$8.6M+6.3%	$8.1M+25.9%	$6.4M+64.0%	$3.9M
Current Liabilities	$3.7M-0.7%	$3.7M+43.8%	$2.6M-56.4%	$6.0M+1544.2%	$364K-65.2%	$1.0M-92.4%	$13.7M+48.3%	$9.3M+10.8%	$8.4M+42.9%	$5.8M+4.1%	$5.6M-34.2%	$8.5M+13.6%	$7.5M+166.4%	$2.8M-27.9%	$3.9M
Non-Current Liabilities	$0	$0	$0-100.0%	$162K-98.6%	$11.3M+144.0%	$4.6M+787.9%	$522K-9.8%	$579K+139.2%	$242K-67.1%	$735K+135.0%	$313K+467.1%	$55K-90.2%	$565K-84.3%	$3.6M	$0
Long-Term Debt	N/A	N/A	N/A	N/A	$250K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$357K-95.8%	$8.5M-14.7%	$10.0M-2.8%	$10.3M-4.6%	$10.8M+909.8%	-$1.3M+89.6%	-$12.8M-47.9%	-$8.6M-26.4%	-$6.8M-36.7%	-$5.0M-27.9%	-$3.9M+43.3%	-$6.9M-3.0%	-$6.7M-30.0%	-$5.1M-39.5%	-$3.7M
Retained Earnings	-$169.9M-9.1%	-$155.7M-6.1%	-$146.7M-7.6%	-$136.3M-1.6%	-$134.1M-49.3%	-$89.8M-14.3%	-$78.6M-22.9%	-$63.9M-24.4%	-$51.4M-22.5%	-$42.0M-25.9%	-$33.3M-31.2%	-$25.4M-28.2%	-$19.8M	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$4.6M-55.1%	$4.1M-66.8%	$5.6M-61.3%	$8.5M-47.2%	$10.3M-42.5%	$12.3M-2.6%	$14.6M+5.6%	$16.1M+21.2%
Current Assets	$3.8M-59.4%	$3.1M-71.9%	$4.7M-65.2%	$7.6M-49.4%	$9.4M-44.2%	$11.1M-2.2%	$13.5M+7.2%	$15.0M+24.6%
Cash & Equivalents	$3.1M+153.3%	$1.5M+175.8%	$602K-59.6%	$1.6M-30.9%	$1.2M+6.2%	$548K-38.0%	$1.5M-38.9%	$2.3M+26.3%
Short-Term Investments	$479K-93.9%	$1.4M-85.8%	$3.9M-66.5%	$5.8M-53.1%	$7.9M-48.3%	$10.2M0.0%	$11.6M+18.3%	$12.4M+26.4%
Accounts Receivable	$13K-46.8%	$16K-91.8%	$13K-91.9%	$15K-45.3%	$25K-28.6%	$188K+876.2%	$165K+319.8%	$27K+9.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.6M-61.4%	$3.7M-0.7%	$3.4M-25.0%	$3.7M-31.0%	$4.2M+21.3%	$3.7M+43.8%	$4.6M+50.7%	$5.3M-50.1%
Current Liabilities	$1.6M-61.4%	$3.7M-0.7%	$3.4M-25.0%	$3.7M-31.0%	$4.2M+21.3%	$3.7M+43.8%	$4.6M+52.8%	$5.3M-49.7%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0	$0-100.0%	$0-100.0%
Total Equity	$3.0M-50.8%	$357K-95.8%	$2.2M-77.9%	$4.8M-55.1%	$6.1M-57.6%	$8.5M-14.7%	$10.0M-7.1%	$10.8M+308.3%
Retained Earnings	-$172.1M-6.9%	-$169.9M-9.1%	-$166.7M-8.2%	-$163.7M-7.0%	-$161.0M-8.1%	-$155.7M-6.1%	-$154.0M-6.7%	-$153.0M-2.5%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

BRTX Cash Flow Statement

BRTX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$11.8M	-$10.8M-31.1%	-$8.2M-28.0%	-$6.4M-8.7%	-$5.9M-77.6%	-$3.3M-69.5%	-$2.0M+71.6%	-$6.9M-35.5%	-$5.1M-32.5%	-$3.9M+23.0%	-$5.0M-60.2%	-$3.1M+3.3%	-$3.2M-20.8%	-$2.7M+16.1%	-$3.2M	N/A
Depreciation & Amortization	N/A	$210K+11.1%	$189K+14.1%	$166K+37.5%	$121K+35.3%	$89K-26.6%	$121K-44.2%	$217K-9.6%	$240K-7.3%	$259K+0.3%	$258K+20.9%	$214K+121.1%	$97K-7.8%	$105K+15.9%	$90K0.0%	$90K
Stock-Based Compensation	N/A	$3.3M+18.2%	$2.8M-63.9%	$7.8M-38.3%	$12.6M-45.4%	$23.1M+3240.9%	$692K-58.3%	$1.7M-30.9%	$2.4M-33.4%	$3.6M+41.9%	$2.5M+29.8%	$2.0M+43.7%	$1.4M+67.4%	$813K-56.0%	$1.8M+304.6%	$457K
Capital Expenditures	N/A	$116K+9.3%	$106K-37.9%	$171K-35.5%	$265K+765.1%	$31K	N/A	$36K+176.9%	$13K+255.8%	$4K-98.1%	$189K-53.7%	$408K+142.4%	$168K+1408.7%	$11K+340.6%	$3K-85.7%	$18K
Free Cash Flow	N/A	-$10.9M-30.8%	-$8.3M-26.3%	-$6.6M-6.8%	-$6.2M-83.8%	-$3.4M	N/A	-$7.0M-35.9%	-$5.1M-32.7%	-$3.9M+25.7%	-$5.2M-47.1%	-$3.5M-3.9%	-$3.4M-26.6%	-$2.7M+15.8%	-$3.2M	N/A
Investing Cash Flow	$7.5M	$8.9M+1629.2%	$515K-84.2%	$3.3M+124.3%	-$13.4M-43607.5%	-$31K	N/A	-$36K-176.9%	-$13K-255.8%	-$4K	N/A	N/A	N/A	-$11K+98.9%	-$1.0M-7146.2%	$14K
Financing Cash Flow	$6.2M	$2.9M-61.3%	$7.4M+214.2%	$2.3M	N/A	$21.3M+324.1%	$5.0M-26.5%	$6.8M+43.0%	$4.8M+11.8%	$4.3M	N/A	N/A	N/A	$2.9M-29.9%	$4.1M	N/A
Share Buybacks	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$4K

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	-$3.8M-37.0%	-$2.4M-2.9%	-$2.9M-70.7%	-$2.7M-44.4%	-$2.8M-19.9%	-$2.3M-47.9%	-$1.7M-44.1%	-$1.9M-45.3%
Depreciation & Amortization	$52K+1.2%	$53K+4.9%	$53K+9.0%	$53K+10.6%	$52K+21.2%	$50K+17.9%	$48K+14.5%	$48K
Stock-Based Compensation	$290K-85.6%	N/A	$400K+40.7%	$469K+44.5%	$2.0M-0.9%	N/A	$284K-81.0%	$324K-78.2%
Capital Expenditures	N/A	$80K+540.7%	$0-100.0%	$0	$36K	$12K-82.2%	$58K+389.3%	N/A
Free Cash Flow	N/A	-$2.5M-5.7%	-$2.9M-65.0%	-$2.7M	-$2.8M	-$2.4M-42.4%	-$1.8M-47.6%	N/A
Investing Cash Flow	$968K-59.1%	$2.4M+56.6%	$2.0M+113.3%	$2.1M-28.3%	$2.4M+148.0%	$1.5M+1907.4%	$937K+4486.0%	$3.0M+263.0%
Financing Cash Flow	$4.4M+306.4%	$923K+830.9%	-$49K	$888K+7015.3%	$1.1M-85.5%	-$126K-252.1%	$0-100.0%	-$13K
Share Buybacks	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Dividends Paid.

BRTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BRTX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	93.4%+0.4pp	93.0%-7.0pp	100.0%	N/A	N/A	N/A	N/A	N/A	100.0%+0.3pp	99.7%+41.3pp	58.4%+9.8pp	48.6%-39.0pp	87.6%-4.0pp	91.6%	N/A
Operating Margin	-4350.1%	-2881.6%	-10439.5%	-15838.1%	-57191.0%	-3574.1%	N/A	N/A	-10338.6%	-21414.0%	-1140.1%	-1183.3%	-282873.2%	-35746.1%	N/A
Net Margin	-3959.4%	-2239.3%	-7145.2%	-11037.0%	-96311.5%	-14639.9%	N/A	N/A	N/A	N/A	-1259.9%	-1343.2%	-342333.0%	N/A	N/A
Return on Equity	-3992.2%-3887.0pp	-105.3%-1.1pp	-104.1%+24.4pp	-128.5%+282.4pp	-410.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-349.1%-276.0pp	-73.1%+9.5pp	-82.6%-2.1pp	-80.5%+116.9pp	-197.3%+62.0pp	-259.3%	N/A	N/A	N/A	N/A	-392.8%-62.6pp	-330.3%+85.6pp	-415.9%	N/A	N/A
Current Ratio	0.84-2.1x	2.97-1.4x	4.37+1.8x	2.53-56.5x	59.01+56.0x	3.05+3.0x	0.010.0x	0.020.0x	0.060.0x	0.010.0x	0.050.0x	0.010.0x	0.030.0x	0.010.0x	0.03
Debt-to-Equity	10.44+10.0x	0.44+0.2x	0.26-0.3x	0.60+0.6x	0.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	0.09+0.1x	0.030.0x	0.010.0x	0.010.0x	0.000.0x	0.02-0.1x	0.090.0x	0.090.0x	0.050.0x	0.02-0.3x	0.31+0.1x	0.25+0.2x	0.000.0x	0.010.0x	0.00
FCF Margin	-3031.7%	-2078.9%	-4527.6%	-5157.2%	-7305.6%	N/A	-5349.5%	-4610.4%	-4762.3%	-14279.8%	-561.3%	-816.4%	-159736.0%	-20441.6%	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Gross Margin	68.1%-20.2pp	91.6%-0.6pp	10.4%-81.8pp	97.1%+4.4pp	88.4%-11.6pp	92.3%	92.2%-7.8pp	92.7%-7.3pp
Operating Margin	-14612.6%	-19516.8%	-31432.3%	-1089.8%	-19230.1%	-6212.8%	-979.0%	-2770.8%
Net Margin	-9298.3%	-16365.5%	-25748.1%	-875.8%	-21359.2%	-3778.6%	-467.2%	-4521.4%
Return on Equity	-71.2%+15.7pp	-899.1%-880.0pp	-137.7%-126.8pp	-54.8%-17.5pp	-86.9%-71.6pp	-19.2%+3.9pp	-10.9%-55.2pp	-37.3%+178.6pp
Return on Assets	-46.4%+5.3pp	-78.6%-65.3pp	-53.8%-46.4pp	-31.2%-6.2pp	-51.7%-39.3pp	-13.3%+4.9pp	-7.5%-42.0pp	-25.0%+17.9pp
Current Ratio	2.35+0.1x	0.84-2.1x	1.37-1.6x	2.07-0.8x	2.24-2.6x	2.97-1.4x	2.95-1.3x	2.82+1.7x
Debt-to-Equity	0.53-0.1x	10.44+10.0x	1.56+1.1x	0.76+0.3x	0.68+0.4x	0.44+0.2x	0.46+0.2x	0.49-3.5x
Asset Turnover	0.010.0x	0.000.0x	0.000.0x	0.040.0x	0.000.0x	0.000.0x	0.020.0x	0.010.0x
FCF Margin	N/A	-12728.8%	-24585.9%	-888.2%	-11260.7%	-5451.0%	-752.6%	N/A

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: The current ratio is below 1.0 (0.84), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
BioRestorative Therapies, Inc. BRTX	FY2025	$360K	-$14.2M	N/A	$2.1M	—
Aptorum Group Limited APM	FY2025	N/A	-$1.4M	N/A	$570K	—
XTL Biopharmaceuticals Ltd. XTLB	FY2025	$451K	N/A	N/A	$4.8M	—
Briacell Therapeutics Corp. BCTX	FY2025	N/A	-$26.3M	N/A	$29.6M	—
BioVie, Inc. BIVI	FY2026	N/A	-$22.1M	N/A	$10.4M	—

Where BioRestorative Therapies, Inc. Ranks

Frequently Asked Questions

What is BioRestorative Therapies, Inc.'s annual revenue?

BioRestorative Therapies, Inc. (BRTX) reported $360K in total revenue for fiscal year 2025. This represents a -10.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BioRestorative Therapies, Inc.'s revenue growing?

BioRestorative Therapies, Inc. (BRTX) revenue declined by 10.3% year-over-year, from $401K to $360K in fiscal year 2025.

Is BioRestorative Therapies, Inc. profitable?

No, BioRestorative Therapies, Inc. (BRTX) reported a net income of -$14.2M in fiscal year 2025.

What is BioRestorative Therapies, Inc.'s EBITDA?

BioRestorative Therapies, Inc. (BRTX) had EBITDA of -$15.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is BioRestorative Therapies, Inc.'s gross margin?

BioRestorative Therapies, Inc. (BRTX) had a gross margin of 93.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is BioRestorative Therapies, Inc.'s return on equity (ROE)?

BioRestorative Therapies, Inc. (BRTX) has a return on equity of -3992.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is BioRestorative Therapies, Inc.'s free cash flow?

BioRestorative Therapies, Inc. (BRTX) recorded an outflow of $10.9M in free cash flow during fiscal year 2025. This represents a -30.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is BioRestorative Therapies, Inc.'s operating cash flow?

BioRestorative Therapies, Inc. (BRTX) recorded an outflow of $10.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are BioRestorative Therapies, Inc.'s total assets?

BioRestorative Therapies, Inc. (BRTX) had $4.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are BioRestorative Therapies, Inc.'s capital expenditures?

BioRestorative Therapies, Inc. (BRTX) invested $116K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does BioRestorative Therapies, Inc. spend on research and development?

BioRestorative Therapies, Inc. (BRTX) invested $10.1M in research and development during fiscal year 2025.

How many shares does BioRestorative Therapies, Inc. have outstanding?

BioRestorative Therapies, Inc. (BRTX) had 25M shares outstanding as of fiscal year 2025.

What is BioRestorative Therapies, Inc.'s current ratio?

BioRestorative Therapies, Inc. (BRTX) had a current ratio of 0.84 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is BioRestorative Therapies, Inc.'s debt-to-equity ratio?

BioRestorative Therapies, Inc. (BRTX) had a debt-to-equity ratio of 10.44 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BioRestorative Therapies, Inc.'s return on assets (ROA)?

BioRestorative Therapies, Inc. (BRTX) had a return on assets of -349.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BioRestorative Therapies, Inc.'s P/E ratio?

BioRestorative Therapies, Inc. (BRTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to March 31, 2026). The market capitalization is $2.1M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is BioRestorative Therapies, Inc.'s price-to-sales ratio?

BioRestorative Therapies, Inc. (BRTX) trades at 5.9x sales, its market capitalization divided by revenue of $358K revenue, trailing 12 months to March 31, 2026. The market capitalization is $2.1M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does BioRestorative Therapies, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, BioRestorative Therapies, Inc. (BRTX) held $3.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.8M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is BioRestorative Therapies, Inc.'s Altman Z-Score?

BioRestorative Therapies, Inc. (BRTX) has an Altman Z-Score of -70.71, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is BioRestorative Therapies, Inc.'s Piotroski F-Score?

BioRestorative Therapies, Inc. (BRTX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BioRestorative Therapies, Inc.'s earnings high quality?

BioRestorative Therapies, Inc. (BRTX) reported a net loss of $14.2M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can BioRestorative Therapies, Inc. cover its interest payments?

BioRestorative Therapies, Inc. (BRTX) reported an operating loss of $15.6M against $266K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.